Who is sponsoring NCT05557552?

NCT05557552 is sponsored by Ruijin Hospital.

What drugs are being tested in NCT05557552?

Interventions in NCT05557552: standar thoracic RT dose, decreased thoracic RT dose.

What condition does NCT05557552 study?

NCT05557552 studies Non-small Cell Lung Cancer Stage III.

Is NCT05557552 still recruiting?

NCT05557552 is currently recruiting now. Last updated 23 September 2024.

Last reviewed 2024-09-23 · How we verify

NCT05557552

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer

Recruiting now NA Last updated 23 September 2024

What this trial tests

NA trial testing standar thoracic RT dose in Non-small Cell Lung Cancer Stage III in 56 participants. Currently enrolling.

Timeline

30 September 2022

Primary endpoint
30 September 2025

30 September 2026

Quick facts

Lead sponsor	Ruijin Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	56
Start date	30 September 2022
Primary completion	30 September 2025
Estimated completion	30 September 2026
Sites	1 location across China

Drugs / interventions tested

standar thoracic RT dose
decreased thoracic RT dose

Conditions studied

Non-small Cell Lung Cancer Stage III — all drugs for Non-small Cell Lung Cancer Stage III →

Sponsor

Ruijin Hospital

Who can join

Adults 18 to 80, any sex, with Non-small Cell Lung Cancer Stage III. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Concurrent chemoradiotherapy without disease progression followed by consolidation durvalumab is standard of care for unresectable, stage III non-small-cell lung cancer (NSCLC) (the 'PACIFIC regimen'). However, many patients with poor performance status, older age or comorbidities may be ineligible for chemotherapy due to expected high toxicity. The present study aim to investigate the efficacy and toxicities of sequential chemo-immunotherapy plus thoracic radiotherapy for elderly and/or frail stage III NSCLC patients unfit for concurrent chemoradiotherapy, and to identify the optimal thoracic dose for this patient population.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Immunotherapy and radiotherapy: An effective combination in cancer treatment.
Li X, Wang C, Yang H, Xue W, et al · · 2025 · cited 2× · PMID 40764050 · DOI 10.1097/cm9.0000000000003609
Sequential chemo-immunotherapy followed by standard versus reduced thoracic radiotherapy for older and/or frail stage III non-small-cell lung cancer: A randomized open-label cohort trial.
Qi WX, Li S, Wang M, Li H, et al · · 2026 · PMID 42201929 · DOI 10.1371/journal.pmed.1005111
Expanding the immunotherapy universe in extensive-stage small cell lung cancer: from chemoimmunotherapy backbone to next-wave combinations.
Chi X, Dong Y, Zhu L, Su D, et al · · 2025 · PMID 41415276 · DOI 10.3389/fimmu.2025.1693401

Verify or expand the search:

Other recruiting trials for Non-small Cell Lung Cancer Stage III

Currently open trials in the same condition.

NCT06908070 — Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab · Phase 4 · recruiting
NCT06634199 — Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients · recruiting
NCT04728724 — Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer · Phase 2 · recruiting
NCT05398094 — Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy · Phase 2 · recruiting
NCT04685070 — Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lun · Phase 2 · active not recruiting

Other Ruijin Hospital trials

Trials by the same sponsor.

NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05557552 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
Last refreshed: 23 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05557552.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing